FL-H.I.G.-CAPITAL
H.I.G. Capital (“H.I.G.“), a leading global alternative investment firm with $60 billion of capital under management, is pleased to announce that it has signed a definitive agreement to sell its German portfolio company ICG Group (the “company” or “ICG”) to SPIE Group, a European leader in multi-technical services in the areas of energy and communications, listed on the Paris stock exchange (Ticker: SPIE). ICG’s management will remain in place and continue to drive the company’s future development. The transaction is subject to clearance by antitrust authorities.
ICG Group was initially launched in 2021, with H.I.G.’s platform investment in Infratech, which builds complex FTTx networks on behalf of public and private German network operators. ICG subsequently acquired comcross, one of Germany’s leading service providers for mobile telecommunication infrastructure. The mobile communication segment was further developed through ICG’s bolt-on investments in telecommunication solutions providers Schwan and TripleA as well as telecommunication network planner DPE. Today, ICG has more than 700 employees in 16 locations throughout Germany, mainly, as well as in the Netherlands, and Croatia. The company has built more than 15,000 mobile communications sites, deployed more than 15,000 kilometers of fiber-optic lines, and connected more than 100,000 households to the fiber-optic network ("homes passed"). ICG’s revenue quadrupled during H.I.G.’s ownership.
Holger Kleingarn, Managing Director at H.I.G., commented, “We are very pleased to have assembled the ICG Group, uniquely offering customers a single point of contact for the entire value chain of digital infrastructure services. Our engagement in ICG underlines H.I.G.’s expertise in identifying strong platforms in key future industries and sustainably expanding them via organic growth and selected acquisitions. We have established ICG Group as the leading enabler of next-generation infrastructures and turnkey network solutions in Germany and beyond. We thank the management team of Vladimir Suznjevic and Gregor Klaßen for the highly trustful and successful partnership and wish them continued success for the next phase of ICG Group’s development.”
Vladimir Suznjevic, Managing Director of ICG Group and responsible for the mobile communication business, commented, "Technologies such as Industry 4.0, autonomous driving, and artificial intelligence require a significant expansion of digital infrastructure in Germany and Europe. In addition, while the 5G mobile communication standard is currently being rolled out, 6G is already in development. In order to best drive the European digitization, a technical integration of mobile communications and fiber-optic infrastructure is key. At ICG, with the support of H.I.G. and now SPIE, we are ideally positioned to continue meeting this requirement for the benefit of our trusted customers."
Gregor Klaßen, Managing Director of Infratech and responsible for its fiber-optic business, commented, "Germany will catch up to the industrialized countries in fiber optic roll-out over the next decade, resulting in an ongoing high demand for experienced and reliable service providers in the areas of fiber optic planning, civil engineering, and installation. We have trusted relationships with our public-sector and corporate clients, allowing us to implement large turnkey networks for them. We thank H.I.G. for the strong support over the past years. We are looking forward to continue ICG’s success story as part of SPIE Group."
About ICG Group
ICG Group, headquartered in Leonberg (Germany), combines the competencies of the leading communication infrastructure service providers: Infratech, comcross, Schwan, TripleA Networks, and DPE. The Group covers the entire value chain from planning and construction to installation and maintenance of infrastructures for fiber-optic, mobile communications, and electricity networks. All units of the Group are characterized by a strong position in their respective segments and long-standing customer relationships. The ICG Group has more than 700 employees in 16 locations throughout Germany, mainly, as well as in the Netherlands, and Croatia. For more information, please visit icg-gruppe.de.
About H.I.G. Capital
H.I.G. Capital is a leading global alternative investment firm with $60 billion of capital under management.* Based in Miami, and with offices in Atlanta, Boston, Chicago, Dallas, Los Angeles, New York, and San Francisco in the United States, as well as international affiliate offices in Hamburg, London, Luxembourg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro, São Paulo, and Dubai, H.I.G. specializes in providing both debt and equity capital to middle market companies, utilizing a flexible and operationally focused/value-added approach:
- H.I.G.’s equity funds invest in management buyouts, recapitalizations and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
- H.I.G.’s debt funds invest in senior, unitranche and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. also manages a publicly traded BDC, WhiteHorse Finance.
- H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.
- H.I.G. Infrastructure focuses on making value-add and core plus investments in the infrastructure sector.
Since its founding in 1993, H.I.G. has invested in and managed more than 400 companies worldwide. The Firm's current portfolio includes more than 100 companies with combined sales in excess of $53 billion. For more information, please refer to the H.I.G. website at hig.com.
*Based on total capital raised by H.I.G. Capital and its affiliates.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240308259866/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom